Secondary Logo

Stimulant Use in Pregnancy

An Under-recognized Epidemic Among Pregnant Women

SMID, MARCELA C., MA, MD, MS*,†,‡; METZ, TORRI D., MD, MS*; GORDON, ADAM J., MD, MPH†,‡

Clinical Obstetrics and Gynecology: March 2019 - Volume 62 - Issue 1 - p 168–184
doi: 10.1097/GRF.0000000000000418
Substance Abuse in Pregnancy
Free

Stimulant use, including cocaine, methamphetamines, ecstasy, and prescription stimulants, in pregnancy is increasingly common. In the United States, stimulants are the second most widely used and abused substances during pregnancy and pregnant women using stimulants in pregnancy are at increased risk of adverse perinatal, neonatal, and childhood outcomes. In this review, we describe the pharmacology, pathophysiology, and epidemiology of stimulants, summarize the maternal and neonatal effects of perinatal stimulant use, and outline treatment options for stimulant use disorders among pregnant women. Development of effective treatment strategies for stimulant use disorders identified among pregnant women are urgently needed.

*Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine

Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine

Informatics, Decision-Enhancement, and Analytic Sciences Center (IDEAS), Salt Lake City VA Health Care System, Salt Lake City, Utah

M.C.S. is supported by Women’s Reproductive Health Research (WRHR K12, 1K12 HD085816) Career Development Program. The remaining authors declare that they have nothing to disclose.

Correspondence: Marcela C. Smid, MA, MD, MS, 30 N 1900 E #2B200, Salt Lake City, UT. E-mail: marcela.smid@hsc.utah.edu

Back to Top | Article Outline

Introduction

Stimulants, including cocaine, ecstasy, methamphetamines and prescription stimulants, are the second most widely used and abused substances in the United States.1 The lifetime prevalence among adults for stimulant use is 29.2%, second only to marijuana 46.9%.1 Also known as “uppers,” stimulants refer to any drug that increases activity of the central nervous system or those with sympathomimetic properties. Stimulants are widely used both for medical purposes including mood disorders, impulse control disorders such as attention deficit disorder, sleep disorders and obesity.2–5 Because of their euphoric effects, they can be used illegally for recreational and performance-enhancing purposes. While the rate of stimulant use is similar between men and women, it is increasingly recognized that women may be disproportionately vulnerable to developing stimulant misuse and abuse due to factors related to hormones6–9 and reinforcement of gender constructs.10–12 Women progress faster from first exposure to addiction than men—known as telescoping—presenting additional challenges to preventing stimulant use disorders.13,14

In 2015, 1.38 million reproductive age (15 to 44 y old) women used a stimulant in past month (misuse of stimulant prescriptions 1.0%; cocaine 0.7%; methamphetamine 0.7%; ecstasy 0.3%).1 In the United States, stimulant use among pregnant women has increased consistent with the nationwide rise in use rates. Stimulant use among pregnant women is of growing public health concern and is associated with several factors including psychiatric comorbidities,15,16 poverty and social isolation,17,18 history of trauma,19 and domestic violence,20,21 all of which impact maternal and child health outcomes. In the 21st century, attention has shifted to the impact of the opioid epidemic on pregnant women22; however, prenatal stimulant use is more common than opioid use.23,24

The purpose of this article is to describe the pharmacology, pathophysiology, and epidemiology of stimulants (cocaine, methamphetamine, prescription stimulant misuse, ecstasy, ephedra, and bath salts), summarize the maternal and neonatal effects of perinatal stimulant use and outline treatment options for stimulant use disorders among pregnant women.

Back to Top | Article Outline

COCAINE

Pharmacology, Pathophysiology, and Epidemiology

Cocaine is derived from the coca bush Erythroxylon coca, which is native to the Andes Mountain of South America. It produces a dramatic prolonged adrenergic stimulation by presynaptic uptake of sympathomimetic neurotransmitters (norepinephrine, serotonin, and dopamine).25,26 The psychoactive effects of cocaine derive from the prolonged effect of dopamine on the brain’s limbic system and cerebral cortex. Cocaine is used in 3 primary preparations: (1) base (crack cocaine) which has a low melting point and when heated, vaporizes allowing it to be smoked and (2) hydrochloride salt which has a high melting point, thus cannot be smoked because it is destroyed by heat, but is water soluble making it easier to dissolve for injection and intranasal use. While crack cocaine possession is associated with higher legal penalties, cocaine base and hydrochloride salt have identical physiological and psychological effects on the mother and fetus. Cocaine rapidly crosses the maternal and fetal blood brain barrier and the placenta by simple diffusion, causing generalized vasoconstriction by directly affecting fetal and maternal blood vessels.27 Vasoconstriction of maternal vessels has indirect effects on the fetus, which may lead to utero-placental insufficiency, acidosis and fetal hypoxia.28

In the 1980s and 1990s, rising cocaine use, particularly in urban and minority communities, and the emergence of the “crack baby” phenomenon ultimately led to the stigmatization of pregnant women with substance use disorders.29 In the general population, 40% of emergency department visits related to substance use are associated with cocaine, making it the leading cause of illicit drug use associated visits.30 Among women who also use opioids for nonmedical purposes, 9.4% of reproductive age women (18 to 44 y) used cocaine in the past 30 days and 7.4% used methamphetamine or other stimulants.31 In 2015, cocaine was the second most common illicit substance used by pregnant women; 3.4% of pregnant women used cocaine in the past month.1 Pregnant women using cocaine or crack cocaine tend to be older, African American and of low socioeconomic status.32,33 While on the decline, cocaine abuse remains the leading cause of antepartum hospitalizations for substance use among pregnant women.34

Back to Top | Article Outline

Cocaine and Perinatal Outcomes

Maternal complications of cocaine use in pregnancy include cardiovascular complications such as hypertension, myocardial infarction and ischemia, renal failure, hepatic rupture, cerebral ischemia/infarction and maternal death.35–41 Cardiovascular complications of cocaine are not dose-dependent and small doses may lead to cardiac morbidity and mortality in otherwise healthy pregnant women.42 Pregnancy may increase the cardiovascular toxicity of cocaine due to cardiac muscle’s sensitivity to cocaine in the presence of increasing progesterone concentrations.43–45 Contractility of papillary muscles of pregnant and nonpregnant progesterone-treated female rats becomes severely compromised at substantially lower cocaine concentrations compared with nonpregnant female rats.46 At the time of cesarean, active cocaine use may lead to combative behavior, cocaine-induced thrombocytopenia, ephedrine-resistant hypotension, and altered pain perception due to altered μ and κ receptors despite adequate pain levels.47 Among pregnant women, cocaine toxicity may cause severe hypertension, hyperreflexia, proteinuria, edema, and seizures, which can be easily confused with preeclampsia.39,48 Beta-adrenergic antagonists, including labetalol and propranolol, should be avoided as they may create unopposed alpha-adrenergic stimulation and are associated with coronary vasoconstriction and end-organ ischemia.47 In the case of suspected maternal cocaine toxicity, hydralazine should be used for the treatment of hypertension.42

Since the 1980s, hundreds of peer-reviewed articles have been published linking maternal cocaine use to adverse pregnancy outcomes. However, many of these studies do not control for important confounders including maternal age, poverty, stress, co-occurring psychiatric comorbidities, other substances including tobacco, alcohol, and other drugs. There is disagreement on whether cocaine use increases the risk of structural malformations,49 although some studies show an increase in urinary tract anomalies,50–52 and other studies show an increase in vascular disruption-type abnormalities, including limb reduction and intestinal atresia.53

Gouin et al’s54 systematic review and meta-analysis of 31 studies found that cocaine use puts women at increased risk for 5 adverse perinatal outcomes: preterm delivery, low birth weight (<2500 g), small for gestational age infants, earlier gestational age at delivery and reduced birth weight. Maternal cocaine use is also associated with increased risk of vertical transmission of HIV, hepatitis, and syphilis.49 Several authors have noted that some women report that cocaine use is associated with shorter labor duration; however, studies suggest that while labor duration appears to be similar, women do present with more advanced cervical dilatation and at an earlier gestational age than women who do not use cocaine.55,56 Some studies also suggest increased risk of miscarriage,57 stillbirth,58 placental abruption,59,60 and uterine rupture.61 In a meta-analysis, after controlling for other factors, increased risk of sudden infant death syndrome could not be associated with cocaine use alone.62

Cocaine is found in breastmilk63 and active illicit drug use, including cocaine use, is considered a contraindication to breastfeeding.64,65

Back to Top | Article Outline

Cocaine Use and Long-term Maternal and Childhood Outcomes

Very little is known about postpartum outcomes among mothers with prenatal cocaine use. Postpartum psychological distress was greater among mothers with prenatal cocaine use compared with mothers not using cocaine.66 Definitive studies of long-term outcomes among children with cocaine exposure remain elusive. Some studies have found that children with prenatal exposure have dysregulated behavior,33,67 growth,68 inhibitory control,69 attention,70 and abstract reasoning.68 In a systematic review of 36 studies of children younger than 6 years of age assessing physical growth, cognition, language skills, motor skills, attention, affect, and neurophysiology, Frank et al71 did not find compelling evidence that prenatal cocaine exposure is associated with adverse outcomes that cannot be attributed to gestational age at delivery, caregiver psychiatric comorbidities, other prenatal exposures (tobacco, marijuana or alcohol) or quality of postnatal environment.

Back to Top | Article Outline

METHAMPHETAMINES

Pharmacology, Pathophysiology, and Epidemiology

Methamphetamine, also known as speed, ice, crank, and crystal meth, is the methylated derivative of dextroamphetamine. Methamphetamine is a central nervous system stimulant and causes the presynaptic concentration of dopamine, serotonin, and norepinephrine. Its use is associated with intense euphoria and energy. It is the only illicit substance that can be manufactured from commonly available items such as over-the-counter cough syrups and decongestants.72 It can be snorted, smoked, used rectally and injected with high bioavailability.72,73 Because of its alpha and beta-adrenergic properties, methamphetamine increases the risk of myocardial infarction, hypertension, cardiomyopathy, and stroke.72 Illicit use of methamphetamine has been strongly linked with severe dental disease74 and increased risk of infection including HIV and Hepatitis C.75,76

Methamphetamine use has escalated in the past 2 decades and represents a serious public health concern among reproductive age women. From 2010 to 2014, the rate of drug overdose involving methamphetamine has doubled.77 In 2015, 1.7 million individuals (0.6% of the population) used methamphetamine in the past year; of those, 52.7% used in the past month.1 From 2005 to 2015 among persons who inject drugs, the proportion reporting injecting methamphetamine increased from 2% to nearly 30%.78 Compared with men, women have lower lifetime (6.6% vs. 4.1%), past year (0.9% vs. 0.4%), and past month use (0.5% vs. 0.2%) use of methamphetamines.1 Women who use methamphetamines are at substantially increased risk of death; they have an observed death rate 26 times that of women who do not use.79 In contrast, men who use methamphetamines have an observed death rate 6 times higher than men who did not use. Among high school students (9th to 12th grade), lifetime use of methamphetamine is 6.8% and is a significant risk factor for adolescent pregnancy.80

Among pregnant women, methamphetamine use has also increased. From 1988 to 2004, hospitalization for amphetamine abuse among pregnant women doubled while cocaine abuse decreased 44%.34 During the same time period, nearly a quarter million pregnant women were admitted to federally funded treatment centers in the United States for methamphetamine treatment, making it the primary substance for which pregnant women seek care.24

Pregnant women using methamphetamine are more likely be white (64%), unemployed, and younger than 24 years old.24,34 They are also more likely to have significant psychiatric disorders,15,81 live in poverty, and have lower perceptions of quality of life. They are also at increased risk for legal complications and have a greater likelihood of substance use among friends and family than those not using.82

Back to Top | Article Outline

Methamphetamine and Perinatal Outcomes

While methamphetamine use among pregnant women is associated with adverse perinatal outcomes including fetal death,83 growth restriction,84 and preterm birth,15 most studies are unable to distinguish between methamphetamine exposure and other factors including maternal comorbidities, other drugs, smoking, contaminant in nonpharmaceutical preparation or poverty.16,85–88 In a single center study, women using methamphetamine in pregnancy were more likely to have a preterm delivery, cesarean delivery, neonatal death and maternal intensive care unit admission. However, this study did not control for other factors including smoking, other drug use or socioeconomic status.88 In a meta-analysis of eight studies, methamphetamine use during pregnancy was associated with earlier gestational age at delivery, lower birth weight and smaller head circumference.89 There was no difference in preeclampsia or other hypertensive disorders of pregnancy in this meta-analysis. However, in a study comparing women who were hospitalized for cocaine and methamphetamine in pregnancy, infant morbidity including premature delivery and poor fetal growth were more common in the cocaine using group, whereas vasoconstrictive effects such as cardiovascular disorders and hypertension complicating pregnancy were more common in the amphetamine using group.34

Several case reports and retrospective studies have suggested increased risk of congenital anomalies with methamphetamine use including cardiac defects,90,91 gastroschisis,92 limb reduction,93 biliary atresia,94 and neural tube defects.95 However, several prospective studies have failed to demonstrate an association between methamphetamine use and anomalies with the exception of cleft palate.15,96,97 Infants with prenatal exposure to methamphetamines may develop a constellation of symptoms including jitteriness, drowsiness, and respiratory distress suggesting amphetamine withdrawal, although very few will require pharmacological intervention.98,99

Methamphatemine is neurotoxic,100,101 making prenatal exposure particularly concerning for fetal brain development. In animal models, maternal use of methamphetamines resulted in preferential concentration of metabolites in the fetal brain.102 Effects on the fetal brain were gestational age dependent; exposure to methamphetamine in early to mid trimester produced long-lasting effects on the serotonergic development of the fetal brain.103 Sex differences in methamphetamine exposure may start in the fetal period. Male offspring with prenatal exposure to methamphetamine may be at increased risk of drug-induced neurotoxicity as adults.104 There is a paucity of neuroimaging studies of children exposed to methamphetamine prenatally. In 2 studies using the same population, smaller subcortical brain volumes and alterations in cellular metabolism in the basal ganglia were noted among methamphetamine-exposed children versus unexposed children.105,106 Notable limitations of these studies include more alcohol and tobacco exposure in the methamphetamine group compared with the control group.

Back to Top | Article Outline

Methamphetamine Use and Long-term Maternal and Child Outcomes

Similar to cocaine, long-term studies of children exposed to methamphetamine are limited. However, the Infant Development, Environment and Lifestyle study (IDEAL) has followed 412 maternal-child pairs (204 methamphetamine exposed vs. 208 unexposed pairs) from the United States and New Zealand longitudinally from delivery through childhood providing valuable insight into maternal postpartum outcomes and infant and child development.82,99,107,108 Infants were matched with controls based on prenatal exposure to alcohol, tobacco, marijuana, and maternal depression. Infants exposed to opioids and cocaine were excluded, limiting the generalizability of study findings. At 1 month of age, one-third of women with prenatal methamphetamine use did not have custody of their children compared with 2% of women with no use.82 Prenatal methamphetamine exposure has been linked to increased likelihood of admission to the neonatal intensive care unit, decreased arousal and increased physiological stress,81,108,109 which subsequently improved at 1 month of age.110 Mothers with prenatal methamphetamine use were also more likely to be depressed which correlated with poorer infant autonomic stress response.111 At age 3, differences in cognitive, behavioral, language, and emotional outcomes between exposed and unexposed children were correlated with adverse social environments and not prenatal methamphetamine exposure.112 However, in subsequent studies of the same IDEAL population, heavy prenatal methamphetamine exposure (≥3 d/wk) was associated with anxiety/depression and attention problems by age 3 and 5 years after controlling for other substances and caregiver/environmental risk factors.113,114 In the IDEAL cohort, children exposed to methamphetamine at age 7.5 years had poorer cognitive function on the Conner’s Parent Rating Scale, but not behavioral problems.115

Several neuroimaging and cognitive function studies have assessed structural brain development of children with prenatal methamphetamine exposure. In a study of children aged 3 to 4, there were no differences in global cognitive functioning between methamphetamine exposed versus control groups.116 Methamphetamine-exposed children did perform worse on visual motor processing tests than control children; however, a large number of tests were performed without adjustment for multiple comparisons.116 While not correlated with functional differences, methamphetamine-exposed female children had changes in frontal white matter suggestive of altered neuronal and glial development. Several studies using neuroimaging to assess structural brain development of children 7 to 15 years old with prenatal methamphetamine exposure have demonstrated alterations in the striatum and frontal lobes with sex differences, suggesting that prenatal methamphetamine exposure leads to (1) rewiring of corticostriatal networks, (2) a differential effect in male and female children, (3) changes that persist into late childhood and adolescence, and (4) structural differences that are correlated with cognitive and functional differences.117–121

Methamphetamines are excreted in the breastmilk122 and, as with cocaine, active illicit drug use is a contraindication to breastfeeding.64,65

Back to Top | Article Outline

PRESCRIPTION STIMULANT MISUSE

Prescription stimulants including a mixture of amphetamine salts (Adderall), lisdexamfetamine (Viviane), and methylphenidate (Ritalin) are primarily used for the treatment of attention deficit and hyperactivity disorder (ADHD), which affect 3% to 7% of young people. Among college students, the lifetime prevalence of nonmedical prescription stimulant use was 6.9% to 8.1%, past year prevalence was 4.1% to 5.4% and past month prevalence was 2.1%.123,124 Nonprescription use of stimulants includes those taking medications not prescribed to the individual or not taking as directed (exceeding quantity, alternative routes such as intranasal). Among reproductive age women, 3% of women have ADHD and in cases of moderate to severe impairment, the benefits of prescription stimulant use may outweigh risks.125 In 2015, 1% of reproductive age women reported prescription stimulant misuse.1

Back to Top | Article Outline

Prescription Misuse Effect on Pregnancy

Very little is known about prescription misuse of stimulants. Most known data about prescription stimulant use are derived from studies of women treated for ADHD during pregnancy. On the basis of several population-based cohort studies, first trimester exposure to prescription stimulants does not appear to be associated with increased risk of congenital anomalies.126–128 Among women taking prescription stimulant medications, there was a small increased risk of preeclampsia and preterm birth.129 Among women who filled at least 2 prescriptions for stimulants between 8 and 18 weeks, the risk of placental abruption increased. Those continuing to the third trimester had an increased risk of preterm delivery. Women in this cohort were receiving prescriptions from medical providers and the proportion of women misusing these medications is unknown.

Among women treated primarily with methylphenidate during pregnancy, there was an increased risk of neonatal seizures and NICU admission in one population-based Swedish cohort study. However, authors acknowledge residual confounding which limits the ability to directly attribute these findings to stimulant use.130 In another Australian study of women with ADHD, treatment with stimulants both before and during pregnancy was associated with adverse outcomes, including preeclampsia and preterm birth, at similar rates, suggesting that stimulant treatment did not account for the increased risk.131 Notably, both of these studies assume that pregnant women take medications as prescribed and markers of misuse (early refills, multiple providers, multiple pharmacies) were not assessed.

Amphetamines are excreted in human breastmilk; however, very limited data are available. A threshold of 20 mg daily is suggested as quantity sufficient to detect metabolites in the neonatal urine, however, this is based on the study of one woman treated for narcolepsy with amphetamine 20 mg daily followed for 6 weeks pospartum.132 Despite known passage into the breastmilk, no adverse neonatal effects were identified in a cohort of 103 breastfed infants with prescription amphetamine exposure.133 While illicit stimulant use, including prescription stimulant misuse is a contraindication to breastfeeding,64,65 use of prescribed stimulants as directed may not be associated with increased risk.

Back to Top | Article Outline

ECSTASY (N-METHYL-3,4- METHYLENEDIOXYAMPHETAMINE; 3,4-METHYLENE-DIOXYMETHAMPHETAMINE)

N-methyl-3,4-methylenedioxyamphetamine; 3,4-methylene-dioxymethamphetamine (MDMA), commonly referred to as Ecstasy, E and Molly, is an amphetamine used for recreational purposes. An estimated 6.4 million people have used MDMA1 and exposure among high school age children has dramatically increased.134 In 2015, 0.3% of reproductive age women used MDMA in the past year.1 Pregnant women who use MDMA during pregnancy are more likely to suffer negative consequences including work and social problems compared with those who did not use MDMA.135

Back to Top | Article Outline

MDMA Effects on Pregnancy

There is limited information on effects of MDMA in pregnancy. In the largest prospective study, 71 women had MDMA only exposure and 56 women had MDMA and other substance exposure. Of continued pregnancies (n=78), 15.4% of infants had congenital anomalies, which is higher than the expected frequency (2% to 3%).134 Cardiovascular (26 per 100 livebirths vs. expected 5 to 10 per 100) and musculoskeletal malformations (38 per 100 livebirths vs. expected 1 per 1000) were most common. There is one additional case report of a congenital heart defect with prenatal MDMA exposure.136 A case-control study found that MDMA exposure was associated with vasoconstrictive disorders including gastroschisis; however, there were only 7 women with prenatal exposure in this cohort.92 There is little known about other pregnancy outcomes or lactation with MDMA.

Back to Top | Article Outline

MDMA and Long-term Maternal and Child Outcomes

Like methamphetamine, MDMA is neurotoxic.137 Little data are available on maternal outcomes after MDMA prenatal use. Several studies have suggested that MDMA is associated with worse infant outcomes, including poorer motor quality and lower milestone attainment, in a dose-dependent manner.135,138 The observed developmental delays particularly in fine and gross motor delays persisted at 24 months.139,140

Back to Top | Article Outline

EPHEDRA

Ephedra, found in several Ephedraceae species, is a commonly used herb in Chinese and Western herbal traditions. In Chinese traditional medicine, it is also known as ma huang. Ephedra contains ephedrine, pseudoephedrine, norephedrine, and norpseudoephedrine. At high doses, ephedra use has been associated with cardiovascular complications and death in the general population.141,142 Among individuals with co-existing psychiatric disorders or in the presence of polysubstance use, ephedra has been associated with psychosis, severe depression, mania and suicidal ideation.143 Among US adults, 3.9% report using ephedra (ma huang).144 Ephedra is reportedly one of the more commonly used herbs with 1.1% of women reporting use 3 months before pregnancy and 0.6% in the first trimester.145 In one study of women using weight loss products, ∼1% of women reported using ephedra-containing products inadvertently in the periconception period. In the National Birth Defects Prevention Study which included 18438 women from 10 states from 199 to 2003, 1.3% reported using ephedra during pregnancy.146 There were 5 cases of anencephaly among women with ephedra use, however, there was no statistically significant association compared with women no using ephedra (odds ratio, 2.8; confidence interval, 1.0-7.3). Very little is known about ephedra use and perinatal outcomes or lactation.

Back to Top | Article Outline

NATURAL AND SYNTHETIC CATHINONES

Natural and synthetic cathinones contain simulants derived from the khat plant (Catha edulis) which is native to East Africa and the Arabian Peninsula. Khat leaves contain 2 stimulants cathinone and methcanthinones and are chewed for mild stimulant properties. Synthetic cathinone, widely known as “bath salts,” are considered part of a group of “new psychoactive substances” that unregulated psychoactive substances with no legitimate medical use.147 They are introduced and then reintroduced in quick succession to obstruct law enforcement. Synthetic cathinones are generally white or brown crystal-like powder and can produce increased friendliness and sex drive, agitation, violent behavior, and hallucinations. They are illegal in most states due to adverse mental and physical effects.148,149 The 3 most popular bath salt constituents include mephedrone, methylone, and 3,4-methylenedioxypyrovalerone (MDPV). Cathinones act at the dopamine, serotonin, and norepinephrine synapses and produce stimulant similar effects to methamphetamines and cocaine.150 One study found that MDPV is 10 times more potent than cocaine at producing locomotor activation, tachycardia, and hypertension in rats.151 MDPV has been implicated in bath salt overdoses in the United States and produces a cocaine-like blockage of transporters for dopamine and norepinephrine. Because of action at the serotonin transporter, bath salt overdose is associated with serotonin syndrome which manifests as agitation, psychosis, hyperthermia, and tachycardia.

The epidemiology of bath salt use is limited. Among high school seniors, 1.1% have used bath salts in the past year.152 In an on-line survey of predominantly educated white males, (N=113), bath salt use was associated with increased sexual desire and high-risk sexual behaviors.153 To our knowledge, there is no available information on the prevalence of bath salt use among reproductive age or pregnant women.

Back to Top | Article Outline

Cathinones and Perinatal Outcomes Pregnancy

Studies from Africa and Middle East demonstrate an association between khat use and decreased uterine blood flow and decrease in birth weight.154–156 A small study (N=642) in Yemen found no increased risk of stillbirth or congenital malformations among pregnant women who chewed khat during their pregnancies.157 Among lactating women who chew khat, norpseudoephedrine has been found in breast milk.158 In a study of women who chewed khat while breastfeeding, 75% women who chewed khat 4 or more times a week had a history of a child dying compared with 7% of women who chewed khat once a week; however, the study did not account for other significant confounders of childhood mortality in this region, including age of children, socioeconomic status, and amount of breastfeeding.159 There are no studies currently available on the maternal, fetal or childhood effects of bath salts.

Back to Top | Article Outline

TREATMENT OF STIMULANT USE DISORDERS AMONG PREGNANT WOMEN

There is no Food and Drug Administration (FDA) approved pharmacotherapy for stimulant use disorder. In the nonpregnant population, studies of pharmacotherapy for cocaine and amphetamine use disorders have largely shown no efficacy for any pharmacotherapy including antidepressants, anticonvulsants, and dopamine agonists inhibitors.160 Psychosocial treatments appear to be the only effective treatment for stimulant use disorders.161 Most notably, contingency management, also known as motivational incentives, provides rewards for desired behaviors (ie, negative drug test) and withholding privileges for undesired behaviors (ie, relapse) appears to be most effective for treatment of stimulant use disorders.162

However, studies often exclude reproductive age women due to fears of unintentional effects on the fetus in the event of unanticipated pregnancy. The growing body of evidence that stimulant use has important gender and sex differences suggests that studies on effective treatment of reproductive age and pregnant women are urgently needed. Clinicians and policymakers should be aware of the impact of stimulant use during pregnancy and significant resources are needed to adequately to address this epidemic.

Back to Top | Article Outline

Conclusions

Stimulant use in pregnancy is an under-recognized public health epidemic and has important short-term and long-term implications for maternal and neonatal health (Table 1). Illicit stimulant use is likely associated with adverse perinatal outcomes including shorter gestational age and low birth weight; however, less is known about prescribed stimulant use and perinatal outcomes. Little is known about safety of stimulant use during breastfeeding. Screening for substance use, including prescription use for nonmedical purposes and illicit stimulant use, is recommended by the American College of Obstetricians and Gynecologist and the American Society for Addiction Medicine.65 Despite these recommendations, the majority of obstetrical providers do not systematically screen pregnant or postpartum women for substance use and are likely to miss women using stimulants if selective screening is based on age, race/ethnicity or socioeconomic status.163,164 Postpartum screening may be particularly important as risk of drug relapse is highest in the postpartum period.165,166 Among women identified at low or moderate risk may respond well to brief intervention, however, those at high risk of a stimulant use disorder likely need referral to treatment.163 Significant research gaps exist regarding stimulant use disorders among pregnant and postpartum women (Table 2). Research studies have systematically excluded pregnant and lactating women from studies on pharmacological therapy for stimulant use disorder despite a growth body of literature showing important sex and gender differences in treatment responses. Systems barriers for pregnant and postpartum women also prevent many women from seeking treatment for stimulant use disorder. In general, many drug treatment programs do not admit pregnant women or parenting women with children. Once they delivered, many women face loss of insurance after pregnancy which may disrupt or preclude substance use treatment. Pregnancy and family-oriented treatment approaches are urgently needed. Furthermore, research studies on novel treatment approaches for stimulant use disorder should systematically include pregnant and postpartum women given the association between adverse perinatal outcomes and untreated stimulant use disorder. Finally, long-term studies that track family-based outcomes are needed to understand the interplay of maternal, paternal and childhood outcomes associated with perinatal stimulant use.

TABLE 1

TABLE 1

TABLE 2

TABLE 2

Back to Top | Article Outline

References

1. Center for Behavioral Health Statistics and Quality. 2015 National survey on drug use and health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.pdf.
2. Fisher BL, Schauer P. Medical and surgical options in the treatment of severe obesity. Am J Surg. 2002;184:S9–S16.
3. McCabe SE, Teter CJ, Boyd CJ. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs. 2006;38:43–56.
4. Arnsten AF. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006;31:2376–2383.
5. Gyllenhaal C, Merritt SL, Peterson SD, et al. Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Med Rev. 2000;4:229–251.
6. Sofuoglu M, Dudish-Poulsen S, Nelson D, et al. Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans. Exp Clin Psychopharmacol. 1999;7:274–283.
7. Evans SM, Foltin RW. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacology. 2006;31:659–674.
8. White TL, Justice AJ, de Wit H. Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav. 2002;73:729–741.
9. Roth ME, Cosgrove KP, Carroll ME. Sex differences in the vulnerability to drug abuse: a review of preclinical studies. Neurosci Biobehav Rev. 2004;28:533–546.
10. Brecht M-L, O’Brien A, Von Mayrhauser C, et al. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29:89–106.
11. Joe KA. Ice is strong enough for a man but made for a woman. Crime Law Social Change. 1994;22:269–289.
12. Miller J, Carbone-Lopez K, Gunderman MVPresser L, Sandberg S. Gendered narratives of self, addiction, and recovery among women methamphetamine users. Narrative Criminology: Understanding Stories of Crime. 2015:69–95.
13. Lynch W, Potenza MN, Cosgrove KP, et alBrady KT, Back SE, Greenfield SF. Sex differences in vulnerability to stimulant abuse. Women and Addiction: A Comprehensive Handbook. New York, NY: Guilford; 2009:409–418.
14. Tuchman E. Women and addiction: the importance of gender issues in substance abuse research. J Addict Dis. 2010;29:127–138–117–.
15. Wright TE, Schuetter R, Tellei J, et al. Methamphetamines and pregnancy outcomes. J Addict Med. 2015;9:111–117.
16. Oei JL, Abdel-Latif ME, Clark R, et al. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child FetalNeonatal Ed. 2009;95:F36–F41.
17. Boeri MW, Tyndall BD, Woodall DR. Suburban poverty: barriers to services and injury prevention among marginalized women who use methamphetamine. West J Emerg Med. 2011;12:284–292.
18. Wermuth L. Poverty and methamphetamine abuse: a study of AIDS risk behaviors among rural Northern California Women. J Poverty. 1999;3:25–45.
19. Kissin WB, Svikis DS, Morgan GD, et al. Characterizing pregnant drug-dependent women in treatment and their children. J Subst Abuse Treat. 2001;21:27–34.
20. Martin SL, English KT, Clark KA, et al. Violence and substance use among North Carolina pregnant women. Am J Public Health. 1996;86:991–998.
21. Hedin LW, Janson PO. Domestic violence during pregnancy: the prevalence of physical injuries, substance use, abortions and miscarriages. Acta Obstet Gynecol Scand. 2000;79:625–630.
22. Krans EE, Patrick SW. Opioid use disorder in pregnancy: health policy and practice in the midst of an epidemic. Obstet Gynecol. 2016;128:4–10.
23. Terplan M. Why is there no moral panic surrounding methamphetamine use in pregnancy in the US? Adiktologie. 2008;8:300–301.
24. Terplan M, Smith EJ, Kozloski MJ, et al. Methamphetamine use among pregnant women. Obstet Gynecol. 2009;113:1285–1291.
25. Gold MS, Washton AM, Dackis CA. Cocaine abuse: neurochemistry, phenomenology, and treatment. Cocaine use in America: epidemiologic and clinical perspectives. NIDA Res Monogr. 1985;61:130–150.
26. Pitts D, Marwah J. Autonomic actions of cocaine. Can J Physiol Pharmacol. 1989;67:1168–1176.
27. Krishna RB, Levitz M, Dancis J. Transfer of cocaine by the perfused human placenta: the effect of binding to serum proteins. Am J Obstet Gynecol. 1993;169:1418–1423.
28. Sheinkopf SJ, Lagasse LL, Lester BM, et al. Prenatal cocaine exposure: cardiorespiratory function and resilience. Ann N Y Acad Sci. 2006;1094:354–358.
29. Chavkin W. Cocaine and pregnancy—time to look at the evidence. JAMA. 2001;285:1626–1628.
30. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No(SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. Available at: https://www.samhsa.gov/data/sites/default/files/DAWN2k11ED/DAWN2k11ED/DAWN2k11ED.htm.
31. Jarlenski M, Barry CL, Gollust S, et al. Polysubstance use among US women of reproductive age who use opioids for nonmedical reasons. Am J Public Health. 2017;107:1308–1310.
32. Day NL, Cottreau CM, Richardson GA. The epidemiology of alcohol, marijuana, and cocaine use among women of childbearing age and pregnant women. Clin Obstet Gynecol. 1993;36:232–245.
33. Richardson GA, Day NL, Mcgauhey PJ. The impact of prenatal marijuana and cocaine use on the infant and child. Clin Obstet Gynecol. 1993;36:302–318.
34. Cox S, Posner SF, Kourtis AP, et al. Hospitalizations with amphetamine abuse among pregnant women. Obstet Gynecol. 2008;111:341–347.
35. Lampley EC, Williams S, Myers SA. Cocaine-associated rhabdomyolysis causing renal failure in pregnancy. Obstet Gynecol. 1996;87:804–806.
36. Moen MD, Caliendo MJ, Marshall W, et al. Hepatic rupture in pregnancy associated with cocaine use. Obstet Gynecol. 1993;82(pt 2 suppl):687–689.
37. Mercado A, Johnson JG, Calver D, et al. Cocaine, pregnancy, and postpartum intracerebral hemorrhage. Obstet Gynecol. 1989;73(pt 2):467–468.
38. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345:351–358.
39. Towers CV, Pircon RA, Nageotte MP, et al. Cocaine intoxication presenting as preeclampsia and eclampsia. Obstet Gynecol. 1993;81:545–547.
40. Slutsker L. Risks associated with cocaine use during pregnancy. Obstet Gynecol. 1992;79(pt 1):778–789.
41. Burkett G, Bandstra ES, Cohen J, et al. Cocaine-related maternal death. Am J Obstet Gynecol. 1990;163:40–41.
42. Kuczkowski KM. The effects of drug abuse on pregnancy. Curr Opin Obstet Gynecol. 2007;19:578–585.
43. Woods JR, Plessinger MA. Pregnancy increases cardiovascular toxicity to cocaine. Am J Obstet Gynecol. 1990;162:529–533.
44. Plessinger MA, Woods JR. Progesterone increases cardiovascular toxicity to cocaine in nonpregnant ewes. Am J Obstet Gynecol. 1990;163:1659–1664.
45. Plessinger MA, Woods JR Jr. The cardiovascular effects of cocaine use in pregnancy. Reprod Toxicol. 1991;5:99–113.
46. Sharma A, Plessinger MA, Sherer DM, et al. Pregnancy enhances cardiotoxicity of cocaine: role of progesterone. Toxicol Appl Pharmacol. 1992;113:30–35.
47. Kuczkowski KM. Anesthetic implications of drug abuse in pregnancy. J Clin Anesth. 2003;15:382–394.
48. Plessinger MA, Woods JJ. Maternal, placental, and fetal pathophysiology of cocaine exposure during pregnancy. Clin Obstet Gynecol. 1993;36:267–278.
49. Bauer CR, Langer JC, Shankaran S, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med. 2005;159:824–834.
50. Chavez G, Mulinare J, Cordero J. Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies. Int J Gynecol Obstet. 1990;31:309.
51. Chavez G, Mulinare J, Cordero J. Maternal cocaine use and the risk for genitourinary tract defects: an epidemiologic approach. Am J Human Genetics. 1988;43:A43.
52. Chávez GF, Mulinare J, Cordero JF. Maternal cocaine use during early pregnancy as a risk factor for congenital urogenital anomalies. JAMA. 1989;262:795–798.
53. Hoyme HE, Jones KL, Dixon SD, et al. Prenatal cocaine exposure and fetal vascular disruption. Pediatrics. 1990;85:743–747.
54. Gouin K, Murphy K, Shah PS. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011;204:340. e1–e12.
55. Dombrowski MP, Wolfe HM, Welch RA, et al. Cocaine abuse is associated with abruptio placentae and decreased birth weight, but not shorter labor. Obstet Gynecol. 1991;77:139–141.
56. Webbeh H, Matthews RP, McCalla S, et al. The effect of recent cocaine use on the progress of labor. Am J Obstet Gynecol. 1995;172:1014–1018.
57. Ness RB, Grisso JA, Hirschinger N, et al. Cocaine and tobacco use and the risk of spontaneous abortion. N Engl J Med. 1999;340:333–339.
58. Bingol N, Fuchs M, Diaz V, et al. Teratogenicity of cocaine in humans. J Pediatr. 1987;110:93–96.
59. Acker D, Sachs BP, Tracey KJ, et al. Abruptio placentae associated with cocaine use. Am J Obstet Gynecol. 1983;146:220–221.
60. Chasnoff IJ, Burns WJ, Schnoll SH, et al. Cocaine use in pregnancy. N Engl J Med. 1985;313:666–669.
61. Gonsoulin W, Borge D, Moise KJ. Rupture of unscarred uterus in primigravid woman in association with cocaine abuse. Am J Obstet Gynecol. 1990;163:526–527.
62. Fares I, McCulloch KM, Raju T. Intrauterine cocaine exposure and the risk for sudden infant death syndrome: a meta-analysis. J Perinatol. 1997;17:179–182.
63. Chasnoff IJ, Lewis DE, Squires L. Cocaine intoxication in a breast-fed infant. Pediatrics. 1987;80:836–838.
64. American Academy of Pediatrics Committee on Durgs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–778.
65. American College of Obstetricians and Gynecologists. Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130:e81–e94.
66. Singer L, Arendt R, Farkas K, et al. Relationship of prenatal cocaine exposure and maternal postpartum psychological distress to child developmental outcome. Dev Psychopathol. 1997;9:473–489.
67. Accornero VH, Anthony JC, Morrow CE, et al. Estimated effect of prenatal cocaine exposure on examiner-rated behavior at age 7 years. Neurotoxicol Teratol. 2011;33:370–378.
68. Richardson GA, Goldschmidt L, Larkby C, et al. Effects of prenatal cocaine exposure on adolescent development. Neurotoxicol Teratol. 2015;49:41–48.
69. Bridgett DJ, Mayes LC. Development of inhibitory control among prenatally cocaine exposed and non-cocaine exposed youths from late childhood to early adolescence: the effects of gender and risk and subsequent aggressive behavior. Neurotoxicol Teratol. 2011;33:47–60.
70. Carmody DP, Bennett DS, Lewis M. The effects of prenatal cocaine exposure and gender on inhibitory control and attention. Neurotoxicol Teratol. 2011;33:61–68.
71. Frank DA, Augustyn M, Knight WG, et al. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613–1625.
72. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104:1085–1099.
73. Elkashef A, Vocci F, Hanson G, et al. Pharmacotherapy of methamphetamine addiction: an update. Subst Abus. 2008;29:31–49.
74. Hart CL, Gunderson EW, Perez A, et al. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology. 2008;33:1847–1855.
75. Miller CL, Kerr T, Fischer B, et al. Methamphetamine injection independently predicts hepatitis C infection among street-involved youth in a Canadian setting. J Adolesc Health. 2009;44:302–304.
76. Anderson R, Flynn NKlee H. The methamphetamine-HIV connection in Northern California. Amphetamine Misuse: International Perspectives on Current Trends. Amsterdam: Harwood Academic Publishers; 1997:181–196.
77. Warner M, Chen LH, Makuc DM, et al. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011;81:1–8.
78. Al-Tayyib A, Koester S, Langegger S, et al. Heroin and methamphetamine injection: an emerging drug use pattern. Subst Use Misuse. 2017;52:1051–1058.
79. Kuo CJ, Liao YT, Chen WJ, et al. Causes of death of patients with methamphetamine dependence: a record‐linkage study. Drug Alcohol Rev. 2011;30:621–628.
80. Zapata LB, Hillis SD, Marchbanks PA, et al. Methamphetamine use is independently associated with recent risky sexual behaviors and adolescent pregnancy. J Sch Health. 2008;78:641–648.
81. Shah R, Diaz SD, Arria A, et al. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012;29:391–400.
82. Derauf C, LaGasse LL, Smith LM, et al. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the infant development, environment, and lifestyle study (IDEAL). Am J Drug Alcohol Abuse. 2007;33:281–289.
83. Gorman MC, Orme KS, Nguyen NT, et al. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014;211:429. e1–e7.
84. Nguyen D, Smith LM, LaGasse LL, et al. Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr. 2010;157:337–339.
85. Barlow A, Mullany BC, Neault N, et al. Examining correlates of methamphetamine and other drug use in pregnant American Indian adolescents. Am Indian Alaska Native Ment Health Res. 2010;17:1–24.
86. McElhatton P. Fetal effects of substances of abuse. J Toxicol Clin Toxicol. 2000;38:194–195.
87. Eriksson M, Larsson G, Zetterström R. Amphetamine addiction and pregnancy. Acta Obstet Gynecol Scand. 1981;60:253–259.
88. Good MM, Solt I, Acuna JG, et al. Methamphetamine use during pregnancy: maternal and neonatal implications. Obstet Gynecol. 2010;116:330–334.
89. Kalaitzopoulos D-R, Chatzistergiou K, Amylidi A-L, et al. Effect of methamphetamine hydrochloride on pregnancy outcome: a systematic review and meta-analysis. J Addict Med. 2018;12:220–226.
90. Gilbert EF, Khoury GH. Dextroamphetamine and congenital cardiac malformations. J Pediatr. 1970;76:638.
91. Nora J, Vargo T, Nora A, et al. Dexamphetamine: a possible environmental trigger in cardiovascular malformations. Lancet. 1970;295:1290–1291.
92. Draper ES, Rankin J, Tonks AM, et al. Recreational drug use: a major risk factor for gastroschisis? Am J Epidemiol. 2007;167:485–491.
93. Bays J. Fetal vascular disruption with prenatal exposure to cocaine or methamphetamine. Pediatrics. 1991;87:416–417.
94. Levin JN. Amphetamine ingestion with biliary atresia. J Pediatr. 1971;79:130–131.
95. Matera R, Zabala H, Jimenez A. Bifid exencephalia. Teratogen action of amphetamine. Int Surg. 1968;50:79–85.
96. Milkovich L, van den Berg BJ. Effects of antenatal exposure to anorectic drugs. Am J Obstet Gynecol. 1977;129:637–642.
97. Little BB, Snell LM. Methamphetamine abuse during pregnancy: outcome and fetal effects. Obstet Gynecol. 1988;72:541–544.
98. Oro AS, Dixon SD. Perinatal cocaine and methamphetamine exposure: maternal and neonatal correlates. J Pediatr. 1987;111:571–578.
99. Smith L, Yonekura ML, Wallace T, et al. Effects of prenatal methamphetamine exposure on fetal growth and drug withdrawal symptoms in infants born at term. J Dev Behav Pediatr. 2003;24:17–23.
100. Jablonski SA, Williams MT, Vorhees CV. Mechanisms involved in the neurotoxic and cognitive effects of developmental methamphetamine exposure. Birth Defects Res C Embryo Today. 2016;108:131–141.
101. Davidson C, Gow AJ, Lee TH, et al. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 2001;36:1–22.
102. Won L, Bubula N, McCoy H, et al. Methamphetamine concentrations in fetal and maternal brain following prenatal exposure. Neurotoxicol Teratol. 2001;23:349–354.
103. Won L, Bubula N, Heller A. Fetal exposure to methamphetamine in utero stimulates development of serotonergic neurons in three‐dimensional reaggregate tissue culture. Synapse. 2002;43:139–144.
104. Heller A, Bubula N, Lew R, et al. Gender-dependent enhanced adult neurotoxic response to methamphetamine following fetal exposure to the drug. J Pharmacol Exp Ther. 2001;298:769–779.
105. Chang L, Smith LM, LoPresti C, et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Res. 2004;132:95–106.
106. Smith L, Chang L, Yonekura M, et al. Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero. Neurology. 2001;57:255–260.
107. Arria AM, Derauf C, LaGasse LL, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J. 2006;10:293–302.
108. LaGasse LL, Wouldes T, Newman E, et al. Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol. 2011;33:166–175.
109. Smith LM, LaGasse LL, Derauf C, et al. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol. 2008;30:20–28.
110. Kiblawi ZN, Smith LM, Diaz SD, et al. Prenatal methamphetamine exposure and neonatal and infant neurobehavioral outcome: results from the IDEAL study. Subst Abus. 2014;35:68–73.
111. Smith LM, Paz MS, LaGasse LL, et al. Maternal depression and prenatal exposure to methamphetamine: neurodevelopmental findings from the infant development, environment, and lifestyle (ideal) study. Depress Anxiety. 2012;29:515–522.
112. Derauf C, LaGasse L, Smith L, et al. Infant temperament and high risk environment relate to behavior problems and language in toddlers. J Dev Behav Pediatr. 2011;32:125–135.
113. LaGasse LL, Derauf C, Smith LM, et al. Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics. 2012;129:681–688.
114. Derauf C, LaGasse LL, Smith LM, et al. Prenatal methamphetamine exposure and inhibitory control among young school-age children. J Pediatr. 2012;161:452–459.
115. Diaz SD, Smith LM, LaGasse LL, et al. Effects of prenatal methamphetamine exposure on behavioral and cognitive findings at 7.5 years of age. J Pediatr. 2014;164:1333–1338.
116. Chang L, Cloak C, Jiang C, et al. Altered neurometabolites and motor integration in children exposed to methamphetamine in utero. Neuroimage. 2009;48:391–397.
117. Roussotte FF, Bramen JE, Nunez SC, et al. Abnormal brain activation during working memory in children with prenatal exposure to drugs of abuse: the effects of methamphetamine, alcohol, and polydrug exposure. Neuroimage. 2011;54:3067–3075.
118. Roussotte FF, Rudie JD, Smith L, et al. Frontostriatal connectivity in children during working memory and the effects of prenatal methamphetamine, alcohol, and polydrug exposure. Dev Neurosci. 2012;34:43–57.
119. Colby JB, Smith L, O’Connor MJ, et al. White matter microstructural alterations in children with prenatal methamphetamine/polydrug exposure. Psychiatry Res. 2012;204:140–148.
120. Roos A, Jones G, Howells FM, et al. Structural brain changes in prenatal methamphetamine-exposed children. Metab Brain Dis. 2014;29:341–349.
121. Roos A, Kwiatkowski MA, Fouche J-P, et al. White matter integrity and cognitive performance in children with prenatal methamphetamine exposure. Behav Brain Res. 2015;279:62–67.
122. Bartu A, Dusci LJ, Ilett KF. Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol. 2009;67:455–459.
123. McCabe SE, Knight JR, Teter CJ, et al. Non‐medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction. 2005;100:96–106.
124. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy. 2006;26:1501–1510.
125. Baker AS, Freeman MP. Management of attention deficit hyperactivity disorder during pregnancy. Obste Gynecol Clin. 2018;45:495–509.
126. Huybrechts KF, Bröms G, Christensen LB, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry. 2018;75:167–175.
127. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals. 2013;6:1221–1286.
128. Pottegård A, Hallas J, Andersen JT, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:88–93.
129. Cohen JM, Hernández-Díaz S, Bateman BT, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017;130:1192–1201.
130. Nörby U, Winbladh B, Källén K. Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics. 2017;140:e20170747.
131. Poulton AS, Armstrong B, Nanan RK. Perinatal outcomes of women diagnosed with attention-deficit/hyperactivity disorder: an Australian population-based cohort study. CNS Drugs. 2018;32:377–386.
132. Steiner E, Villen T, Hallberg M, et al. Amphetamine secretion in breast milk. Eur J Clin Pharmacol. 1984;27:123–124.
133. Ayd FJ Jr. Excretion of psychotropic drugs in human breast milk. Psychopharm Rev. 1973;8:33–40.
134. Landry MJ. MDMA: a review of epidemiological data. J Psychoactive Drugs. 2002;34:163–169.
135. Singer LT, Moore DG, Fulton S, et al. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol. 2012;34:303–310.
136. van Tonningen MR, Garbis H, Reuvers M. Ecstasy exposure during pregnancy. Teratology. 1998;58:33A.
137. Colado M, O’shea E, Granados R, et al. A study of the neurotoxic effect of MDMA (“ecstasy”) on 5‐HT neurones in the brains of mothers and neonates following administration of the drug during pregnancy. Br J Pharmacol. 1997;121:827–833.
138. Singer LT, Moore DG, Min MO, et al. One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics. 2012;130:407–413.
139. Singer LT, Moore DG, Min MO, et al. Developmental outcomes of 3, 4‐methylenedioxymethamphetamine (ecstasy)‐exposed infants in the UK. Human Psychopharmacol Clin. 2015;30:290–294.
140. Singer LT, Moore DG, Min MO, et al. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016;54:22–28.
141. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833–1838.
142. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with Ma Huang, an herbal source of ephedrine. Paper presented at Mayo Clinic Proceedings, 2002.
143. Maglione M, Miotto K, Iguchi M, et al. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. Am J Psychiatry. 2005;162:189–191.
144. Kennedy J. Herb and supplement use in the US adult population. Clin Ther. 2005;27:1847–1858.
145. Broussard CS, Louik C, Honein MA, et al. NBDP Study. Herbal use before and during pregnancy. Am J Obstet Gynecol. 2010;202:443.e1–e6.
146. Bitsko RH, Reefhuis J, Louik C, et al. Periconceptional use of weight loss products including ephedra and the association with birth defects. Birth Defects Res A Clin Mol Teratol. 2008;82:553–562.
147. National Institute on Durg Abuse, National Institutes of Health; US. Department of Health and Human Services. Synthetic cathinones “Bath salts”. 2018. Available at: https://www.drugabuse.gov/publications/drugfacts/synthetic-cathinones-bath-salts.
148. Miller BL, Stogner JM, Miller JM, et al. The arrest and synthetic novel psychoactive drug relationship: observations from a young adult population. J Drug Issues. 2017;47:91–103.
149. John ME, Thomas-Rozea C, Hahn D. Bath salts abuse leading to new-onset psychosis and potential for violence. Clin Schizophr Relat Psychoses. 2017;11:120–124.
150. Miotto K, Striebel J, Cho AK, et al. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013;132:1–12.
151. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013;38:552–562.
152. Palamar JJ. “Bath salt” use among a nationally representative sample of high school seniors in the United States. Am J Addict. 2015;24:488–491.
153. Johnson PS, Johnson MW. Investigation of “bath salts” use patterns within an online sample of users in the United States. J Psychoactive Drugs. 2014;46:369–378.
154. Khawaja M, Al-Nsour M, Saad G. Khat (Catha edulis) chewing during pregnancy in Yemen: findings from a national population survey. Matern Child Health J. 2008;12:308–312.
155. Hassan N, Gunaid A, Murray Lyon I. Khat (Catha edulis): health aspects of khat chewing. East Mediterr Health J. 2007;13:706–718.
156. Mwenda JM, Arimi MM, Kyama MC, et al. Effects of khat (Catha edulis) consumption on reproductive functions: a review. East Afr Med J. 2003;80:318–323.
157. Nakajima M, Jebena MG, Taha M, et al. Correlates of khat use during pregnancy: a cross-sectional study. Addict Behav. 2017;73:178–184.
158. Kristiansson B, Abdul Ghani N, Eriksson M, et al. Use of khat in lactating women: a pilot study on breast-milk secretion. J Ethnopharmacol. 1987;21:85–90.
159. Ibrahim Ali Omer M, Mansoub MA, Omer R, et al. The effect of qat chewing and other factors on breast-feeding and child survival in a Yemeni society. Sudan J Paediatr. 2011;11:14–20.
160. de Lima MS, de Oliveira Soares BG, Reisser AA, et al. Pharmacological treatment of cocaine dependence: a systematic review. Addiction. 2002;97:931–949.
161. Dutra L, Stathopoulou G, Basden SL, et al. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179–187.
162. Prendergast M, Podus D, Finney J, et al. Contingency management for treatment of substance use disorders: a meta‐analysis. Addiction. 2006;101:1546–1560.
163. Wright TE, Terplan M, Ondersma SJ, et al. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016;215:539–547.
164. Madsen AM, Stark LM, Has P, et al. Opioid knowledge and prescribing practices among obstetrician-gynecologists. Obstet Gynecol. 2018;131:150–157.
165. Schiff DM, Nielsen T, Terplan M, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol. 2018;132:466–474.
166. Platner M, Loucks TL, Lindsay MK, et al. Pregnancy-associated deaths in rural, nonrural, and metropolitan areas of Georgia. Obstet Gynecol. 2016;128:113–120.
Keywords:

pregnancy; substance use disorder; methamphetamine; cocaine; bath salts; ecstasy

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.